Immunome, Inc.
Immunome, Inc. (IMNM) Revenue
Annual & quarterly revenue history · segment & region breakdown
IMNM · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsImmunome, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 23.23% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.01B | -$0.00B | -23.23% |
| 2024-12-31 | $0.01B | -$0.00B | -35.50% |
| 2023-12-31 | $0.01B | +$0.01B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare IMNM revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Immunome, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Immunome, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Immunome, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IMNM revenue · 4 questionsIMNM's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 23.23% year-over-year from $0.01B in FY2025.
▸ Source: FMP · Immunome, Inc. SEC filings · GAAP · Immunome, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026